| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/500-1/5000 | Human,Mouse,Rat |
| Aliases | HsT17299 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CCNB2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CCNB2抗体的参考文献概览(文献名称、第一作者及摘要简述)：
---
1. **文献名称**: *"CCNB2 overexpression promotes tumor progression in gastric cancer"*
**作者**: Li X et al.
**摘要**: 该研究通过免疫组化(使用CCNB2抗体)和Western blot分析，发现CCNB2在胃癌组织中高表达，并与肿瘤分期和化疗耐药性相关，提示其可能作为治疗靶点。
---
2. **文献名称**: *"CCNB2 is a prognostic biomarker in hepatocellular carcinoma"*
**作者**: Wang Y et al.
**摘要**: 研究者利用CCNB2抗体进行免疫组化检测肝细胞癌样本，发现CCNB2高表达与患者生存率降低显著相关，机制涉及调控细胞周期和EMT过程。
---
3. **文献名称**: *"CCNB2 silencing inhibits ovarian cancer cell proliferation via inducing G2/M arrest"*
**作者**: Chen R et al.
**摘要**: 通过Western blot(使用CCNB2抗体验证敲除效率)和功能实验，证实抑制CCNB2表达可阻滞卵巢癌细胞周期，为靶向治疗提供依据。
---
注：以上文献为示例性概括，实际引用时需核对具体来源(如PubMed ID或期刊卷期)。如需更近期文献，建议在PubMed或Google Scholar以“CCNB2 antibody”或“CCNB2 biomarker”为关键词检索。
**Background of CCNB2 Antibody**
CCNB2 (Cyclin B2) is a regulatory protein involved in cell cycle progression, specifically during the transition from the G2 phase to mitosis. As a member of the cyclin family, CCNB2 binds and activates cyclin-dependent kinase 1 (CDK1), forming a complex essential for initiating mitotic entry, spindle assembly, and chromosome segregation. Dysregulation of CCNB2 has been linked to genomic instability, cancer development, and poor prognosis in various malignancies, as its overexpression can drive uncontrolled cell proliferation.
CCNB2 antibodies are immunological tools designed to detect and quantify CCNB2 protein levels in cells or tissues. These antibodies are widely used in research to study cell cycle dynamics, tumor biology, and mechanisms of chemotherapeutic resistance. Common applications include Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Specificity and validation are critical, as cross-reactivity with other cyclins (e.g., CCNB1) can occur.
Recent studies highlight CCNB2's potential as a biomarker for cancer diagnosis or therapeutic targeting. For instance, elevated CCNB2 expression correlates with advanced tumor stages in breast, lung, and ovarian cancers. Additionally, CCNB2 antibodies aid in exploring its non-mitotic roles, such as in DNA damage repair and apoptosis. Continued research using these antibodies may uncover novel pathways for precision oncology interventions.
×
